BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 11709141)

  • 1. [Therapeutic advances of nuclear medicine in oncology].
    Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
    Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic nuclear medicine in pediatric malignancy.
    Schmidt M; Baum RP; Simon T; Howman-Giles R
    Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):411-28. PubMed ID: 20823809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
    Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
    Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
    Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 131I-MIBG scintigraphy in neural crest tumours.
    Samuel AM; Murugesan S; Kurkure PA; Advani SH; Sonawane GA; Noronha OP
    Indian J Cancer; 1994 Jun; 31(2):103-10. PubMed ID: 7927441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
    Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
    Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear medicine therapy of neuroblastoma.
    Hoefnagel CA
    Q J Nucl Med; 1999 Dec; 43(4):336-43. PubMed ID: 10731784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nuclear medicine in oncotherapy].
    Pávics L; Besenyi Z
    Magy Onkol; 2015 Sep; 59(3):193-7. PubMed ID: 26339908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy in nuclear medicine--current status and future prospects.
    Oyen WJ; Bodei L; Giammarile F; Maecke HR; Tennvall J; Luster M; Brans B
    Ann Oncol; 2007 Nov; 18(11):1782-92. PubMed ID: 17434893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
    Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
    J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
    Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
    Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear medicine imaging in pediatric oncology.
    Troncone L; Rufini V; Turba R; Mastrangelo R; Riccardi R; Donfrancesco F
    J Nucl Biol Med (1991); 1994 Mar; 38(1):76-84. PubMed ID: 8075180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
    Bardiès M; Buvat I
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
    [No Abstract]   [Full Text] [Related]  

  • 16. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
    Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors.
    Zagar I; Han R; Mitrovic S
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):13-6. PubMed ID: 9002742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of medullary carcinoma of the thyroid with I-131 MIBG.
    Thomas CC; Cowan RJ; Albertson DA; Cooper MR
    Clin Nucl Med; 1994 Dec; 19(12):1066-8. PubMed ID: 7874804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
    Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.
    Gaze MN; Gains JE; Walker C; Bomanji JB
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):66-78. PubMed ID: 23474636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.